Teladoc Health Expands Comprehensive Weight Care Program with Employer Contribution Option for GLP-1 Medications
Key Highlights
- ➤Teladoc expands employer contribution option for FDA-approved GLP-1 medications
- ➤Employers set fixed payment per employee per fill, improving spending predictability
- ➤First contracted employer clients launch programs January 1, 2027
- ➤47.7% of members achieved at least 5% weight loss by 24 months
- ➤Lilly and Novo medications available alongside Teladoc’s comprehensive clinical support
Expert Statements
Kelly Bliss, President, U.S. Group Health at Teladoc Health
“Employers want to provide benefits that help their workforce achieve their health goals and need flexible strategies that work for their organizations”
Kelly Bliss, President, U.S. Group Health at Teladoc Health
“We are helping employers meet the needs of their employees while providing greater predictability and transparency around healthcare spending. Importantly, we give people a trusted path to high-quality care and affordable access to FDA-approved, authentic medication for meaningful, sustained health outcomes.”
Kevin Hern, Senior Vice President, Lilly Employer, Lilly USA
“Too many people still lack coverage for obesity care, and Lilly is working to close that access gap”
Kevin Hern, Senior Vice President, Lilly Employer, Lilly USA
“Lilly Employer Connect gives employers greater choice, control and cost transparency in how they support access for their employees, and we’re pleased Teladoc Health is helping bring that flexibility to its clients.”
Tom Scales, SVP Market Access and Public Affairs for Novo
“Expanding access to obesity care requires options that work for patients and employers”
Tom Scales, SVP Market Access and Public Affairs for Novo
“Novo works with approved collaborators like Teladoc to provide pathways specifically designed for employer-funded access, giving employers a clear and predictable way to manage their costs and help their employees afford obesity care.”
NEW YORK, Nov. 17, 2026 (GLOBE NEWSWIRE) -- Teladoc Health (NYSE: TDOC), the global leader in virtual care, today announced an expansion of its Comprehensive Weight Care program that gives employers a new way to offer access to FDA-approved GLP-1 medications and comprehensive weight care while keeping medication spending predictable.
Teladoc Health's Comprehensive Weight Care program now gives employers the option to contribute toward the cost of GLP-1 medications outside of traditional pharmacy benefit designs with flexible patient out of pocket costs. This offering enables employers to help employees and their families pay for authentic FDA-approved GLP-1 medications from Eli Lilly and Company and Novo, alongside comprehensive clinical care, nutrition and lifestyle support.
Get started
Create a free account to read the full story.
